SavedAdd your journal

Journals / BEYOGLU EYE JOURNAL / 2018 / Cilt: 3 - Sayı: 2

Anterior Chamber Dislocation of Ozurdex Implant: A Case Report

Elif ERTAN
Rahmi DUMAN
Reşat DUMAN
MUSTAFA DOĞAN
Pages
96–98
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Presently described is a case of corneal toxicity occurring after the migration of a dexamethasone implant into the anterior chamber

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Anterior chamber dislocation of an Ozurdex (Allergan plc, Dublin, Ireland) implant from the vitreous cavity is unusual.
📊
Key Findings & Data:The risk factors for dexamethasone implant migration into the anterior chamber include a defective posterior lens capsule, aphakia, and a prior history of pars plana vitrectomy.
💡
Conclusion & Impact:Presently described is a case of corneal toxicity occurring after the migration of a dexamethasone implant into the anterior chamber
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Anterior chamber dislocation of an Ozurdex (Allergan plc, Dublin, Ireland) implant from the vitreous cavity is unusual. The risk factors for dexamethasone implant migration into the anterior chamber include a defective posterior lens capsule, aphakia, and a prior history of pars plana vitrectomy. Presently described is a case of corneal toxicity occurring after the migration of a dexamethasone implant into the anterior chamber

🔖

Cite This Article

ERTAN, E., DUMAN, R., DUMAN, R., DOĞAN, M. (2018). Anterior Chamber Dislocation of Ozurdex Implant: A Case Report. BEYOGLU EYE JOURNAL, Cilt: 3 - Sayı: 2, 96–98. https://ajindex.com/articles/146240

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther 2011;28:351–66.
  2. Schmitz K, Maier M, Clemens CR, Höhn F, Wachtlin J, Lehmann F, et al; German Retinal Vein Occlusion Group. Reliability and safety of intravitreal Ozurdex injections. The ZERO study [Article in German]. Ophthalmologe 2014;111:44–52. [CrossRef] Agrawal R, Fernandez-Sanz G, Bala S, Addison PK. Desegmentation of Ozurdex implant in vitreous cavity: report of two cases. Br J Ophthalmol 2014;98:961–3. [CrossRef] Coca-Robinot J, Casco-Silva B, Armadá-Maresca F, GarcíaMartínez J. Accidental injections of dexamethasone intravitreal implant (Ozurdex) into the crystalline lens. Eur J Ophthalmol 2014;24:633–6. [CrossRef] Khurana RN, Appa SN, McCannel CA, Elman MJ, Wittenberg SE, Parks DJ, et al. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology 2014;121:67–71. [CrossRef] Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453–60. [CrossRef] Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, et al; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904–14. [CrossRef] Pardo-López D, Francés-Muñoz E, Gallego-Pinazo R, Díaz-Llopis M. Anterior chamber migration of dexametasone intravitreal implant (Ozurdex®). Graefes Arch Clin Exp Ophthalmol 2012;250:1703–4. [CrossRef] Bansal R, Bansal P, Kulkarni P, Gupta V, Sharma A, Gupta A. Wandering Ozurdex(®) implant. J Ophthalmic Inflamm Infect 2012;2:1–5. [CrossRef] Pacella F, Agostinelli E, Carlesimo SC, Nebbioso M, Secondi R, Forastiere M, et al. Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report. J Med Case Rep 2016;10:282. [CrossRef]